Haizheng Pharmaceutical announced that the fourth extraordinary shareholders' meeting of the company in 2026 reviewed and passed a bill to authorize the introduction of Xuanjing Bionucleic Acid patented technology platform and RGN6669 products. A total of 631 shareholders and agents attended the meeting. The total number of voting shares held was 462,195,275 shares, accounting for 39.90% of the company's total voting shares, and 99.8479% of the votes approved by the bill. The procedures for convening, holding and voting at this shareholders' meeting were legal and compliant, and the resolution was legal and valid.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.